Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | HTR2C | P28335 | 3/20 | 0.49 |
| ▸ | HTR2B | P41595 | 3/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22565664 | 0.89 | CYP2A6 (0.50) | GRM5KMT2AHRH1SLC6A4HTR2A | |
| SCHEMBL4121728 | 0.85 | GRM5 (0.46) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4121819 | 0.83 | GRM5 (0.43) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4121817 | 0.83 | GRM5 (0.43) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4109748 | 0.81 | GRM5 (0.43) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4109746 | 0.81 | GRM5 (0.43) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL13507070 | 0.81 | HTR2A (0.46) | KMT2AHRH1SLC6A4HTR2AHTR2C | |
| SCHEMBL4130787 | 0.80 | GRM5 (0.42) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4130794 | 0.80 | GRM5 (0.42) | GRM5KMT2AHRH1SLC6A4MEN1 | |
| SCHEMBL4130789 | 0.80 | GRM5 (0.42) | GRM5KMT2AHRH1SLC6A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| WO-2025007777-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-10-03 | — | — | US | disclosed |
| CN-118660872-A | Pyrimidine compound, preparation method and medical application thereof | 江苏亚虹医药科技股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | LOMOND THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4400504-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PFIZER (US) | 2024-06-06 | — | — | US | disclosed |
| CN-117751104-A | Compound with kinase inhibition function and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2005087226-A1 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004034963-A2 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003092606-A2 | CHOLINESTERASE INHIBITORS TO PREVENT INJURIES CAUSED BY CHEMICALS | EISAI CO., LTD. (JP) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003024450-A1 | METHODS FOR TREATING PRION DISEASES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | GRM5 3724/4885KMT2A 4537/4885HRH1 364/4885 |
| US-20240270699-A1 | COMPOUNDS HAVING N-ARYLPYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC AGENTS | IRAK3, IRAK1, IRAK2 | GRM5 1617/4885KMT2A 560/4885HRH1 596/4885 |
| US-20240182468-A1 | COMPOUNDS FOR THE ACTIVATION OF AMPK | PRKAG1, PRKAG2, PRKAB1 | GRM5 2979/4885KMT2A 3136/4885HRH1 4766/4885 |
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | GRM5 88/4885KMT2A 3316/4885HRH1 219/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | GRM5 1922/4885KMT2A 3061/4885HRH1 2948/4885 |
| US-20240327412-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | GRM5 4657/4885KMT2A 2640/4885HRH1 2287/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | GRM5 2662/4885KMT2A 3205/4885HRH1 2598/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | GRM5 812/4885KMT2A 2169/4885HRH1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.